IL6R and systemic-onset juvenile idiopathic arthritis: Moreover, IL6R is the target of an FDA-approved therapy (Tocilizumab) for the treatment of several diseases, e.g. rheumatoid arthritis and systemic juvenile idiopathic arthritis.